Alcoholism
Conditions
Brief summary
This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
Interventions
Sponsors
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* Meets the criteria for alcohol dependence. * Abstinent from alcohol for a period of at least 5 days and not greater than 30 days. * Able to read English and complete study evaluations. * A stable residence and a telephone to ensure that subjects can be located during the study.
Exclusion criteria
* Currently meets criteria for substance abuse or dependence with the exception of nicotine dependence. * Current use of disulfiram (Antabuse) or a MAO Inhibitor. * Psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal, current mania). * Major depression at the time of assessment. * Previous treatment with naltrexone (Revia) for alcohol dependence. * Significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac disease. * Abstinent longer than 30 days prior to admission to program. * Hepatocellular disease or elevated bilirubin levels. * Females who are pregnant, nursing, or not using a reliable method of birth control.
Countries
United States
Outcome results
None listed